Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CEO of Elite Pharma ELTP said the co. would be boughtout/ merger within 2 1/2 years
Transcipts avail if needed.
CEO OF Elite Pharma ELTP said the co. would be sold or mergered within 2 1/2 years
If you need transcript just ask
GLTA
CEO OF ELTP- ELITE PHARMA mentioned the co. would be sold before 2 1/2 years
If you need copy for transcripts please ask I can supply
ELTP
Up from recent low of 3 cents
BuyOut per the CEO in 2 years
Its Gonna Get Real !!!!!!!!!!!!!!!!!!!
Its been laid out on a silver platter for anyone.
ELTP
Congrats if your still holding..
GLTY
Dont tease me with too good to be true buyathon prices.
New space is 34,000 ft with nearly 20 ft ceilings so if you stack high double the space
thats two stores high
Calendar or Fiscal ??
BUY OUT IN LESS THAT 2 1/2 YEARS !!!!!!!!!!!!!!!!1
“50+ Million for the year ending Mar 31, 2024”
BuyOut Less than 2 1/2 years
Reality setting in yet?? There always next Year, right ?
Still working with Drexel as needed
4 ANDAs filed 4 under review
More in queue
$50+ million dollar year !!!!!
Co. valuation continues to rise.
ELTP
3X capacity !
Increase in efficiency.
Naltrexone in short supply
We now have Two Packaging lines !
ELTP
Beer
Lobster
Snow Crabs
I just took on another 100K
Thx
Biggest Quarter in Elites History !!
ELTP
Two MonsterQuarters in a row !
Gap filled. Blue Skies ahead
ELTP
Elite Pharmaceuticals, Inc. Reports Financial Results For Third Quarter Of Fiscal Year 2024 Ended December 31, 2023 And Provides Conference Call Information
Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST
NORTHVALE, NJ / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the third quarter of fiscal year 2024 ended December 31, 2023 ("Third Quarter").
Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year. Operating profits were $3.5 million, an increase of $1.6 million or 80% from the comparable period of the prior year. The increase in operating profits was primarily attributed to increased revenues achieved from the sale of Elite Laboratories label products, which were launched during the current fiscal.
Conference Call Information
Elite's management will host a conference call to discuss the Third Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
Date: February 15, 2024
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
Financial questions by 7:00 PM EST on Wednesday, February 14, 2024
Audio Replay: https://elite.irpass.com/events_presentations
Bullish
Prasco will Double our Adderall sales this quarter !
It’s about to get real !
GLTY
ELTP
TWO Monster Quarters in a row.
Last quarter was not a fluke.
ELTP
Update on $5.1 Billion dollar drug at 11:30am
X 1. Cash Flow Positive Status - 4 years
X 2. Purchase main building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Generate revenues over $20 million/quarter
__13. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__14. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 15. Lease additional manufacturing and storage space for new ANDAs Jan 2024 - 5 years
__16. European distribution Dexcel partnership approval by Israeli Health
__17. Full ownership of Adderall IR $ 335 Million
__18. Full ownership of Adderall XR $ 1.56 Billion
__19. Generic Concerta- $1.2 BILLION FDA submission
__20. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__21. $100 million in yearly revenues
__22. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__23. Patented Unique ADF (w/o naltrexone)-- NDA
__24. Mikah ANDA (s)
__25. Undisclosed ANDAs/NDAs
__26. Antimetabolite ANDA- Methotrexate -$600 Million
__27. Undisclosed Antimetabolite ANDA- $42 Million
__28. Generic Vyvanse Approval
__29. DollarLand PPS
__30. Uplist to the NASDAQ Exchange
__31. THE Buy Out !
__32. Vegas Baby !!!!!!!
Bullish
Elite Pharmaceuticals, Inc. Reports Financial Results For Third Quarter Of Fiscal Year 2024 Ended December 31, 2023 And Provides Conference Call Information
Conference Call Scheduled for Thursday, February 15 at 11:30 AM EST
NORTHVALE, NJ / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the third quarter of fiscal year 2024 ended December 31, 2023 ("Third Quarter").
Consolidated revenues for the three-month period ended December 31, 2023, were $15.5 million, an increase of $6.3 million or 68% as compared to the comparable period of the prior fiscal year. Operating profits were $3.5 million, an increase of $1.6 million or 80% from the comparable period of the prior year. The increase in operating profits was primarily attributed to increased revenues achieved from the sale of Elite Laboratories label products, which were launched during the current fiscal.
Conference Call Information
Elite's management will host a conference call to discuss the Third Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
Date: February 15, 2024
Time: 11:30 AM EST
Dial-in numbers: 1-800-346-7359 (domestic)
1-973-528-0008 (international)
Conference number: 98840
Questions: dianne@elitepharma.com
Financial questions by 7:00 PM EST on Wednesday, February 14, 2024
Audio Replay: https://elite.irpass.com/events_presentations
Cash Cow ! ELTP
X 1. Cash Flow Positive Status - 4 years
X 2. Purchase main building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Generate revenues over $20 million/quarter
__13. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__14. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
X 15. Lease additional manufacturing and storage space for new ANDAs Jan 2024 - 5 years
__16. European distribution Dexcel partnership approval by Israeli Health
__17. Full ownership of Adderall IR $ 335 Million
__18. Full ownership of Adderall XR $ 1.56 Billion
__19. Generic Concerta- $1.2 BILLION FDA submission
__20. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__21. $100 million in yearly revenues
__22. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__23. Patented Unique ADF (w/o naltrexone)-- NDA
__24. Mikah ANDA (s)
__25. Undisclosed ANDAs/NDAs
__26. Antimetabolite ANDA- Methotrexate -$600 Million
__27. Undisclosed Antimetabolite ANDA- $42 Million
__28. Generic Vyvanse Approval
__29. DollarLand PPS
__30. Uplist to the NASDAQ Exchange
__31. THE Buy Out !
__32. Vegas Baby !!!!!!!
It’s been a year +.
God Bless him and his family.
ELTP
Have you awarded Knighthood to anyone yet ?
ELTP
BuyAThon !
post history is very telling
Or are you a last second buyer ?
Posters have gotten more excited since 3 cents.
Your sentiment seems to deteriorate the higher we go.
Is the King of the Boiler room ridin' you ?
If your in the US we can help otherwise its all up to you.
See what happened to Lowenstein after SEC crack down
What we do know : This is THE Best quarter in Elites history by million$
Mine are holding for The BuyOut.
Ups and downs in between are not important to those after maximum rto investment
Here are the things you could miss out on.
2-4 X's MAYBE BY tomorrow
X 1. Cash Flow Positive Status - 4 years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirkov
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
__11. Generate revenues over $20 million/quarter
__12. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million
__13. Prevail over Purdue in Generic OxyContin infringement suit
__14. Purchase or rent additional manufacturing and storage space for new ANDAs
__15. European distribution Dexcel partnership approval by Israeli Health
__16. Full ownership of Adderall IR $ 335 Million
__17. Full ownership of Adderall XR $ 1.56 Billion
__18. Generic Concerta- $1.2 BILLION FDA submission
__19. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
__20. $100 million in yearly revenues
__21. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
__22. Patented Unique ADF (w/o naltrexone)-- NDA
__23. Mikah ANDA (s)
__24. Undisclosed ANDAs/NDAs
__25. Antimetabolite ANDA- Methotrexate -$600 Million
__26. Undisclosed Antimetabolite ANDA- $42 Million
__27. Generic Vyvanse Approval
__28. DollarLand PPS
__29. Uplist to the NASDAQ Exchange
__30. THE Buy Out !
__31. Vegas Baby !!!!!!!
BULLISH ELTP
https://www.timeanddate.com/countdown/payday?iso=20240214T1630&p0=179&msg=HammerTime++%21%21%21%21&font=cursive
GLTY
How long does it take to stump break a goat. Mean Average is oK
throw away the top and bottom 2
We have not started the yearly revenue games yet. Hold that bid till we start.
Please dont whack yourself tomorrow.